CTSO
Cytosorbents Corporation
Price Chart
Latest Quote
$0.44
-0.04 (-8.11%)
Current Price
| Previous Close | $0.48 |
| Open | $0.46 |
| Day High | $0.50 |
| Day Low | $0.44 |
| Volume | 132,442 |
Stock Information
| Shares Outstanding | 62.79M |
| Total Debt | $29.28M |
| Cash Equivalents | $4.81M |
| Revenue | $37.20M |
| Net Income | $-11.85M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $27.52M |
| EPS (TTM) | $-0.18 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $51.99M |
| Sales | $37.20M |
| Income | $-11.85M |
| Book/sh | $0.04 |
| Cash/sh | $0.08 |
| Employees | 129 |
Financial Ratios
| Quick Ratio | 0.73 |
| Current Ratio | 1.09 |
| Debt/Eq | 1334.37 |
Returns & Margins
| ROA | -18.33% |
| ROE | -141.58% |
| Gross Margin | 71.00% |
| Operating Margin | -34.34% |
| Profit Margin | -31.85% |
Ownership
| Insider Ownership | 15.27% |
| Institutional Ownership | 26.41% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.74 |
| P/B | 12.52 |
Analyst Data
| Recommendation | none |
| Target Price | $2.88 |
Technical Indicators
| SMA20 | $0.46 |
| SMA50 | $0.54 |
| SMA200 | $0.70 |
| RSI | 42.93 |
| ATR | 0.0664 |
| Shares Float | 55.09M |
| Short Float | 3.40% |
| Short Ratio | 20.89 |
| Rel Volume | 0.52 |
Performance History
| Week | +12.89% |
| Month | -7.40% |
| Quarter | -31.35% |
| 6 Months | -31.56% |
| YTD | -33.23% |
| Year | -63.50% |
| 3 Years | -87.23% |
| 5 Years | -94.75% |
| 10 Years | -89.79% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.44 | 145,600 |
| 2026-06-17 | $0.48 | 194,700 |
| 2026-06-16 | $0.52 | 1,641,500 |
| 2026-06-15 | $0.43 | 228,500 |
| 2026-06-12 | $0.40 | 440,500 |
| 2026-06-11 | $0.39 | 441,200 |
| 2026-06-10 | $0.41 | 76,800 |
| 2026-06-09 | $0.42 | 94,800 |
| 2026-06-08 | $0.41 | 43,500 |
| 2026-06-05 | $0.46 | 77,800 |
| 2026-06-04 | $0.49 | 262,600 |
| 2026-06-03 | $0.49 | 1,155,300 |
| 2026-06-02 | $0.48 | 30,700 |
| 2026-06-01 | $0.47 | 65,800 |
| 2026-05-29 | $0.49 | 67,400 |
| 2026-05-28 | $0.50 | 139,500 |
| 2026-05-27 | $0.49 | 148,200 |
| 2026-05-26 | $0.46 | 101,000 |
| 2026-05-22 | $0.46 | 115,400 |
| 2026-05-21 | $0.46 | 139,500 |
| 2026-05-20 | $0.47 | 91,400 |
| 2026-05-19 | $0.47 | 38,200 |
About Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
đ° Latest News
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
GuruFocus.com âĸ 2026-05-14T05:02:46ZTranscript: CytoSorbents Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T21:36:10Z
Cytosorbents (CTSO) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-03-26T14:40:05Z
Cytosorbents Corporation Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-26T12:30:00Z
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ...
GuruFocus.com âĸ 2026-03-26T03:01:42ZCytoSorbents: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-25T20:33:51ZAnalysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long
Simply Wall St. âĸ 2026-02-14T12:16:14Z
CytoSorbents Corp (CTSO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
GuruFocus.com âĸ 2025-11-14T05:03:31Z
Cytosorbents (CTSO) Q3 2025 Earnings Transcript
Motley Fool âĸ 2025-11-13T22:14:09Z
CytoSorbents: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-13T21:58:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $10,572,000 | $10,708,000 | $9,131,716 | $13,955,752 |
| Cost Of Revenue | $10,572,000 | $10,708,000 | $9,131,716 | $13,955,752 |
| Total Revenue | $37,063,000 | $35,595,000 | $31,084,953 | $29,359,910 |
| Operating Revenue | $37,063,000 | $35,595,000 | $31,084,953 | $29,359,910 |
| Expenses | ||||
| Interest Expense | $2,612,000 | $1,399,000 | $157,891 | - |
| Total Expenses | $51,302,000 | $52,047,000 | $63,033,573 | $60,881,789 |
| Other Income Expense | $8,252,000 | $-4,559,000 | $2,046,012 | $-2,515,886 |
| Other Non Operating Income Expenses | $-559,000 | $-334,000 | $96,755 | $-67,303 |
| Net Non Operating Interest Income Expense | $-2,612,000 | $-1,399,000 | $-157,891 | $132,597 |
| Interest Expense Non Operating | $2,612,000 | $1,399,000 | $157,891 | - |
| Operating Expense | $40,730,000 | $41,339,000 | $53,901,857 | $46,926,037 |
| Total Other Finance Cost | - | - | $157,891 | $-132,597 |
| Other Operating Expenses | - | - | $-5,264,426 | $-5,328,899 |
| General And Administrative Expense | - | - | $37,872,361 | $37,136,029 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Net Interest Income | $-2,612,000 | $-1,399,000 | $-157,891 | $132,597 |
| Normalized Income | $-16,594,883 | $-16,812,807 | $-31,143,387 | $-30,442,355 |
| Net Income From Continuing And Discontinued Operation | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Total Operating Income As Reported | $-14,749,000 | $-16,452,000 | $-31,948,620 | $-31,521,879 |
| Net Income Common Stockholders | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Net Income | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Net Income Including Noncontrolling Interests | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Net Income Continuous Operations | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Pretax Income | $-8,599,000 | $-22,410,000 | $-30,060,499 | $-33,905,168 |
| Special Income Charges | $-510,000 | $0 | - | - |
| Operating Income | $-14,239,000 | $-16,452,000 | $-31,948,620 | $-31,521,879 |
| Gross Profit | $26,491,000 | $24,887,000 | $21,953,237 | $15,404,158 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.13 | $-0.38 | $-0.65 | $-0.75 |
| Basic EPS | $-0.13 | $-0.38 | $-0.65 | $-0.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $414,117 | $-318,807 | $52,630 | $-78,355 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,167,000 | $-15,042,000 | $-29,828,443 | $-27,941,667 |
| Total Unusual Items | $8,811,000 | $-4,225,000 | $1,949,257 | $-2,448,583 |
| Total Unusual Items Excluding Goodwill | $8,811,000 | $-4,225,000 | $1,949,257 | $-2,448,583 |
| Reconciled Depreciation | $1,631,000 | $1,744,000 | $2,023,422 | $1,131,629 |
| EBITDA (Bullshit earnings) | $-4,356,000 | $-19,267,000 | $-27,879,186 | $-30,390,250 |
| EBIT | $-5,987,000 | $-21,011,000 | $-29,902,608 | $-31,521,879 |
| Diluted Average Shares | $62,231,771 | $54,434,609 | $44,656,391 | $43,789,997 |
| Basic Average Shares | $62,231,771 | $54,434,609 | $44,656,391 | $43,789,997 |
| Diluted NI Availto Com Stockholders | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Tax Provision | $-401,000 | $-1,691,000 | $-813,739 | $-1,092,585 |
| Restructuring And Mergern Acquisition | $510,000 | $0 | - | - |
| Gain On Sale Of Security | $9,321,000 | $-4,225,000 | $1,949,257 | $-2,448,583 |
| Research And Development | $5,085,000 | $7,607,000 | $15,594,442 | $15,118,907 |
| Selling General And Administration | $35,645,000 | $33,732,000 | $38,307,415 | $37,136,029 |
| Other Gand A | - | - | $37,872,361 | $37,136,029 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,677,000 | $7,386,000 | $19,574,662 | $30,984,440 |
| Total Assets | $44,182,000 | $47,372,000 | $52,956,322 | $63,231,530 |
| Total Non Current Assets | $23,548,000 | $25,768,000 | $27,557,811 | $29,471,839 |
| Other Non Current Assets | $1,575,000 | $1,534,000 | $1,483,958 | $1,687,459 |
| Goodwill And Other Intangible Assets | $3,226,000 | $3,721,000 | $3,906,552 | $4,390,533 |
| Other Intangible Assets | $3,226,000 | $3,721,000 | $3,906,552 | $4,390,533 |
| Current Assets | $20,634,000 | $21,604,000 | $25,398,511 | $33,759,691 |
| Other Current Assets | $1,554,000 | $3,271,000 | $1,834,485 | $2,488,597 |
| Restricted Cash | $0 | $5,000,000 | $0 | - |
| Inventory | $5,281,000 | $2,733,000 | $3,375,817 | $3,461,586 |
| Receivables | $7,550,000 | $7,320,000 | $6,057,072 | $5,664,941 |
| Accounts Receivable | $7,550,000 | $7,320,000 | $6,057,072 | $5,664,941 |
| Allowance For Doubtful Accounts Receivable | $-164,000 | $-158,000 | $-49,663 | $-76,041 |
| Gross Accounts Receivable | $7,714,000 | $7,478,000 | $6,106,735 | $5,740,982 |
| Cash Cash Equivalents And Short Term Investments | $6,249,000 | $3,280,000 | $14,131,137 | $22,144,567 |
| Cash And Cash Equivalents | $6,249,000 | $3,280,000 | $14,131,137 | $22,144,567 |
| Non Current Prepaid Assets | - | $22,644 | $52,051 | $46,914 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $10,418,000 | $10,716,000 | - | - |
| Total Debt | $29,111,000 | $26,893,000 | $18,313,152 | $18,250,944 |
| Long Term Debt And Capital Lease Obligation | $28,570,000 | $26,440,000 | $15,439,516 | $18,142,005 |
| Long Term Debt | $16,667,000 | $13,996,000 | $2,542,857 | $5,000,000 |
| Current Debt And Capital Lease Obligation | $541,000 | $453,000 | $2,873,636 | $108,939 |
| Current Debt | - | - | $2,500,000 | - |
| Other Current Borrowings | - | - | $2,500,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $38,279,000 | $36,265,000 | $29,475,108 | $27,856,557 |
| Total Non Current Liabilities Net Minority Interest | $28,570,000 | $26,440,000 | $15,439,516 | $18,142,005 |
| Current Liabilities | $9,709,000 | $9,825,000 | $14,035,592 | $9,714,552 |
| Other Current Liabilities | $905,000 | $635,000 | $991,545 | - |
| Current Deferred Liabilities | $332,000 | $683,000 | $1,380,821 | $1,516,772 |
| Payables And Accrued Expenses | $7,931,000 | $8,054,000 | $8,789,590 | $8,088,841 |
| Payables | $2,869,000 | $3,340,000 | $3,802,170 | $2,505,803 |
| Accounts Payable | $2,869,000 | $3,340,000 | $3,802,170 | $2,505,803 |
| Interest Payable | - | - | $34,444 | $5,556 |
| Other Payable | - | - | - | $21,871 |
| Equity | ||||
| Common Stock Equity | $5,903,000 | $11,107,000 | $23,481,214 | $35,374,973 |
| Total Equity Gross Minority Interest | $5,903,000 | $11,107,000 | $23,481,214 | $35,374,973 |
| Stockholders Equity | $5,903,000 | $11,107,000 | $23,481,214 | $35,374,973 |
| Gains Losses Not Affecting Retained Earnings | $-2,977,000 | $4,252,000 | $529,321 | $2,329,195 |
| Other Equity Adjustments | $-2,977,000 | $4,252,000 | $529,321 | $2,329,195 |
| Retained Earnings | $-312,207,000 | $-304,009,000 | $-283,289,661 | $-253,997,878 |
| Other | ||||
| Ordinary Shares Number | $62,804,305 | $55,102,933 | $54,510,117 | $43,852,808 |
| Share Issued | $62,804,305 | $55,102,933 | $54,510,117 | $43,852,808 |
| Tangible Book Value | $2,677,000 | $7,386,000 | $19,574,662 | $30,984,440 |
| Invested Capital | $22,570,000 | $25,103,000 | $28,524,071 | $40,374,973 |
| Working Capital | $10,925,000 | $11,779,000 | $11,362,919 | $24,045,139 |
| Capital Lease Obligations | $12,444,000 | $12,897,000 | $13,270,295 | $13,250,944 |
| Total Capitalization | $22,570,000 | $25,103,000 | $26,024,071 | $40,374,973 |
| Additional Paid In Capital | $321,024,000 | $310,809,000 | $306,187,314 | $287,000,021 |
| Capital Stock | $63,000 | $55,000 | $54,240 | $43,635 |
| Common Stock | $63,000 | $55,000 | $54,240 | $43,635 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $11,903,000 | $12,444,000 | $12,896,659 | $13,142,005 |
| Current Deferred Revenue | $332,000 | $683,000 | $1,380,821 | $1,516,772 |
| Current Capital Lease Obligation | $541,000 | $453,000 | $373,636 | $108,939 |
| Current Accrued Expenses | $5,062,000 | $4,714,000 | $4,987,420 | $5,583,038 |
| Net PPE | $18,747,000 | $20,513,000 | $22,115,250 | $23,346,933 |
| Accumulated Depreciation | $-5,146,000 | $-4,226,000 | $-3,036,030 | $-1,896,692 |
| Gross PPE | $23,893,000 | $24,739,000 | $25,151,280 | $25,243,625 |
| Leases | $6,308,000 | $6,283,000 | $6,224,863 | $6,201,523 |
| Other Properties | $10,924,000 | $11,511,000 | $12,058,896 | $12,603,901 |
| Machinery Furniture Equipment | $6,661,000 | $6,945,000 | $6,867,521 | $6,438,201 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-12,000 | $0 | - | - |
| Finished Goods | $3,528,000 | $1,660,000 | $1,851,145 | $1,567,871 |
| Work In Process | $1,014,000 | $503,000 | $838,871 | $1,280,368 |
| Raw Materials | $751,000 | $570,000 | $685,801 | $613,347 |
| Other Inventories | - | $-304,312 | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,868,000 | $-15,097,000 | $-22,591,372 | $-34,689,858 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,377,000 | $-14,428,000 | $-21,655,136 | $-28,234,282 |
| Cash Flow From Continuing Operating Activities | $-12,377,000 | $-14,428,000 | $-21,655,136 | $-28,234,282 |
| Operating Gains Losses | $-9,321,000 | $4,225,000 | $-1,949,257 | $2,580,886 |
| Investing Activities | ||||
| Capital Expenditure | $-491,000 | $-669,000 | $-936,236 | $-6,455,576 |
| Investing Cash Flow | $-415,000 | $-669,000 | $-936,236 | $-6,455,576 |
| Cash Flow From Continuing Investing Activities | $-415,000 | $-669,000 | $-936,236 | $-6,455,576 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,392,000 | $179,000 | $14,255,932 | - |
| Financing Cash Flow | $9,309,000 | $9,331,000 | $14,474,210 | $4,959,642 |
| Cash Flow From Continuing Financing Activities | $9,309,000 | $9,331,000 | $14,474,210 | $4,959,642 |
| Net Common Stock Issuance | $5,392,000 | $179,000 | $14,255,932 | $-40,358 |
| Common Stock Issuance | $5,392,000 | $179,000 | $14,255,932 | - |
| Net Other Financing Charges | - | $-848,000 | - | - |
| Repurchase Of Capital Stock | - | - | - | $-40,358 |
| Other | ||||
| Repayment Of Debt | $0 | $-5,000,000 | $0 | $0 |
| Issuance Of Debt | $2,478,000 | $15,000,000 | $0 | $5,000,000 |
| Interest Paid Supplemental Data | $2,082,000 | $1,290,000 | $376,668 | $0 |
| End Cash Position | $7,771,000 | $9,764,000 | $15,615,095 | $23,832,026 |
| Beginning Cash Position | $9,764,000 | $15,615,000 | $23,832,026 | $53,825,166 |
| Effect Of Exchange Rate Changes | $1,490,000 | $-85,000 | $-99,769 | $-262,924 |
| Changes In Cash | $-3,483,000 | $-5,766,000 | $-8,117,162 | $-29,730,216 |
| Proceeds From Stock Option Exercised | $1,439,000 | $0 | $218,278 | $0 |
| Net Issuance Payments Of Debt | $2,478,000 | $10,000,000 | $0 | $5,000,000 |
| Net Long Term Debt Issuance | $2,478,000 | $10,000,000 | $0 | $5,000,000 |
| Long Term Debt Payments | $0 | $-5,000,000 | $0 | $0 |
| Long Term Debt Issuance | $2,478,000 | $15,000,000 | $0 | $5,000,000 |
| Net Intangibles Purchase And Sale | $-327,000 | $-385,000 | $-398,121 | $-368,211 |
| Purchase Of Intangibles | $-327,000 | $-385,000 | $-398,121 | $-368,211 |
| Net PPE Purchase And Sale | $-88,000 | $-284,000 | $-538,115 | $-6,087,365 |
| Sale Of PPE | $76,000 | $0 | - | - |
| Purchase Of PPE | $-164,000 | $-284,000 | $-538,115 | $-6,087,365 |
| Change In Working Capital | $-1,030,000 | $-4,379,000 | $2,649,141 | $-3,561,557 |
| Change In Other Current Assets | $2,000 | $1,000 | $-49 | $52,678 |
| Change In Payables And Accrued Expense | $-706,000 | $-1,808,000 | $1,607,366 | $-3,248,978 |
| Change In Prepaid Assets | $1,791,000 | $-1,352,000 | $1,104,167 | $-22,187 |
| Change In Inventory | $-2,540,000 | $500,000 | $183,273 | $945,352 |
| Change In Receivables | $423,000 | $-1,720,000 | $-245,616 | $-1,288,422 |
| Other Non Cash Items | $820,000 | $492,000 | $42,857 | - |
| Stock Based Compensation | $2,765,000 | $3,760,000 | $4,155,342 | $3,800,091 |
| Asset Impairment Charge | $956,000 | $449,000 | $670,119 | $627,252 |
| Depreciation Amortization Depletion | $1,631,000 | $1,744,000 | $2,023,422 | $1,131,629 |
| Depreciation And Amortization | $1,631,000 | $1,744,000 | $2,023,422 | $1,131,629 |
| Amortization Cash Flow | $262,000 | $235,000 | - | - |
| Amortization Of Intangibles | $262,000 | $235,000 | - | - |
| Depreciation | $1,369,000 | $1,509,000 | $2,023,422 | $1,131,629 |
| Net Foreign Currency Exchange Gain Loss | $-9,321,000 | $4,225,000 | $-1,949,257 | $2,448,583 |
| Net Income From Continuing Operations | $-8,198,000 | $-20,719,000 | $-29,246,760 | $-32,812,583 |
| Gain Loss On Sale Of PPE | - | - | $0 | $132,303 |
| Common Stock Payments | - | - | - | $-40,358 |
| Changes In Account Receivables | - | - | - | $-1,288,422 |
Fetched: 2026-06-17